1Florida Alzheimer's Disease Research Center

1佛罗里达阿尔茨海默病研究中心

• 批准号: 10413187
• 负责人: GLENN E. SMITH
• 金额: $ 298.72万
• 依托单位: UNIVERSITY OF FLORIDA
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-06-15 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10413187
• 关键词: African American population; Alzheimer' s Disease; Alzheimer' s disease patient; Alzheimer' s disease related dementia; Alzheimer' s disease risk; Amyloid; Autopsy; Biological Markers; Brain; Caring; Caucasians; Cognitive; Collaborations; Communities; Cultural Diversity; Data; Data Analyses; Data Set; Databases; Dementia; Diagnosis; Disease; Educational Activities; Enrollment; Environment; Epidemic; Etiology; European; Evaluation; Family; Florida; Fostering; Funding; Future; Genetic Variation; Goals; Grant; Health Professional; Hispanic; Hispanic Populations; Impaired cognition; Incidence; Individual; Institution; International; Intervention; Knowledge; Language; Lewy Body Dementia; Linguistics; Longitudinal cohort; Longitudinal cohort study; Magnetic Resonance Imaging; Medical; Medical center; Minority Groups; Mission; Natural History; Neuropsychological Tests; Not Hispanic or Latino; Participant; Pathogenesis; Patients; Pilot Projects; Population; Population Heterogeneity; Positron-Emission Tomography; Publications; Research; Research Personnel; Resources; Risk Factors; Scanning; Science; Scientist; Specialized Center; Training; Translating; Underrepresented Minority; United States; United States National Institutes of Health; Universities; Vascular Diseases; Work; accurate diagnosis; base; career development; cognitive change; cohort; comorbidity; data portal; data sharing; disease heterogeneity; ethnic diversity; follow-up; human old age (65+); imaging study; improved; innovation; inter-institutional; member; novel; novel marker; racial and ethnic; racial diversity; ranpirnase; recruit; response; retention rate; skills; tool; training opportunity; web portal

With ~560,000 Alzheimer’s disease (AD) patients and >4 million residents >65 years old, Florida is, and will continue to be, an epicenter of the AD epidemic in the United States. The 1Florida ADRC is a collaboration between Florida institutions, including the University of Florida (UF), Mt. Sinai Medical Center in Miami Beach (MSMC), University of Miami (UM), Florida International University (FIU), and Florida Atlantic University (FAU). The 1Florida ADRC’s global mission is to work with other ADRCs and stakeholders in the AD field to help change the understanding of AD and related dementias (ADRDs) to a new reality in which ADRDs are more facilely and accurately diagnosed, more effectively treated, and ultimately preventable or curable. Much of what we know about the natural history of AD, risk factors for cognitive decline, and response to interventions has come from study of Caucasian populations, largely of European descent. Multiple studies suggest a higher incidence of dementia among Hispanics and other underrepresented minority populations (URM), but whether these findings are broadly generalizable is unclear. Our successful recruitment and evaluation of a majority Hispanic cohort has enabled us to begin to evaluate whether there are differences in ADRDs between Hispanics and non- Hispanics in South Florida. Enhancing our understanding of dementia in ethnically and racially diverse populations is a major theme of our ADRC that will be expanded to include African Americans. As we transition towards an ADRC potentially funded as a P30, we will leverage our successful institutional and investigator partnerships to further expand our recruitment and longitudinal follow up of participants with ethnic, linguistic, cultural, and genetic diversity, as well as comorbidities associated with AD (e.g., vascular disease, Lewy Body Dementia (LBD)). Our overall specific aims are to: 1) Elucidate novel markers for the earliest prodromal stages of cognitive impairment and identify predictors of decline in our ethnically and racially diverse participants, who present with no or varied comorbidities. These longitudinal cohort studies, biomarker studies, and neuropathological studies will help the field to better understand AD, comorbidities, and disease heterogeneity. 2) Enhance our institutional research environments and provide resources to foster a) unique training opportunities; b) career development; and c) novel and innovative research in ADRDs with a growing emphasis on cross-disciplinary team science and advanced data analysis approaches. 3) Provide data, research tools and biospecimens to, and interact with, a wide variety of stakeholders within and outside (e.g., NACC, NCRAD) of our collaborating institutional network. 4) Provide educational activities relevant to ADRDs to health professionals, those in training, and to lay community members, with the goals of improving knowledge, developing skills, and building stronger coalitions to deliver better diagnoses and care to patients and their families.

佛罗里达州拥有约 560,000 名阿尔茨海默病 (AD) 患者和超过 400 万>65 岁的居民 仍然是美国AD流行的中心。 1Florida ADRC 是一项合作 佛罗里达州机构之间的合作，包括佛罗里达大学 (UF)、迈阿密海滩西奈山医疗中心 (MSMC)、迈阿密大学 (UM)、佛罗里达国际大学 (FIU) 和佛罗里达大西洋大学 (FAU)。 1佛罗里达 ADRC 的全球使命是与 AD 领域的其他 ADRC 和利益相关者合作，帮助变革 对 AD 和相关痴呆症 (ADRD) 的理解到了一个新的现实，其中 ADRD 更容易、更容易 准确诊断，更有效治疗，最终是可以预防或治愈的。很多我们所知道的 关于 AD 的自然史、认知能力下降的危险因素以及对干预措施的反应来自 对白种人群体（主要是欧洲人后裔）的研究。多项研究表明，该病的发生率较高 西班牙裔和其他代表性不足的少数族裔 (URM) 中存在痴呆症，但这些发现是否 是否具有广泛的普遍性还不清楚。我们成功招募和评估了大多数西班牙裔群体 使我们能够开始评估西班牙裔和非裔美国人的 ADRD 是否存在差异 南佛罗里达州的西班牙裔人。增强我们对不同种族和种族的痴呆症的了解 人口是我们 ADRC 的一个主要主题，该主题将扩大到包括非裔美国人。当我们转型时 对于可能作为 P30 资助的 ADRC，我们将利用我们成功的机构和研究人员 伙伴关系，以进一步扩大我们对具有种族、语言、 文化和遗传多样性，以及与 AD 相关的合并症（例如血管疾病、路易体病） 痴呆症（LBD））。我们的总体具体目标是：1）阐明最早前驱阶段的新标志物 认知障碍并确定我们的种族和种族多样化参与者中认知功能下降的预测因素，他们 没有或有多种合并症。这些纵向队列研究、生物标志物研究和 神经病理学研究将有助于该领域更好地了解 AD、合并症和疾病异质性。 2) 加强我们的机构研究环境并提供资源以促进 a) 独特的培训 机会； b) 职业发展； c) ADRD 的新颖和创新研究日益受到重视 跨学科团队科学和先进的数据分析方法。 3）提供数据、研究工具和 向组织内外的各种利益相关者（例如 NACC、NCRAD）提供生物样本并与之互动 我们的合作机构网络。 4) 提供与 ADRD 相关的健康教育活动 专业人士、接受培训的人员以及非专业社区成员，以提高知识为目标， 发展技能，建立更强大的联盟，为患者及其家属提供更好的诊断和护理 家庭。